SCHEMBL96180

SCHEMBL96180

Cc1ccc(C(O)c2ccc(C)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.50
TDP1 Q9NUW8 1/20 0.50
CHRNA7 P36544 1/20 0.48
MLKL Q8NB16 1/20 0.46
KMT2A Q03164 1/20 0.44
BRD4 O60885 1/20 0.43
LMNA P02545 2/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
ALOX5 P09917 1/20 0.40
ELANE P08246 1/20 0.40
ALDH1A1 P00352 1/20 0.39
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
CA2 P00918 1/20 0.39
LPL P06858 1/20 0.39
LIPG Q9Y5X9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29699724 0.97 ACHE (0.47) ACHETDP1CHRNA7MLKLKMT2A
SCHEMBL24562816 0.89 LMNA (0.43) ACHETDP1CHRNA7MLKLKMT2A
SCHEMBL477385 0.89 LMNA (0.50) ACHEMLKLKMT2ALMNATSHR
SCHEMBL477533 0.89 LMNA (0.50) ACHEMLKLKMT2ALMNATSHR
SCHEMBL11419617 0.89 ACHE (0.65) ACHETDP1CHRNA7BRD4LMNA
SCHEMBL477590 0.89 LMNA (0.50) ACHEMLKLKMT2ALMNATSHR
SCHEMBL30910858 0.87 CES2 (0.50) TDP1MLKLBRD4LMNATSHR
SCHEMBL21831189 0.87 ACHE (0.62) ACHETDP1CHRNA7MLKLKMT2A
SCHEMBL5351433 0.87 ALDH1A1 (0.62) ACHETDP1CHRNA7MLKLKMT2A
SCHEMBL12981660 0.87 ACHE (0.62) ACHETDP1CHRNA7MLKLKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0136381-B1 POLYOLEFIN COMPOSITIONS MILLIKEN RESEARCH CORPORATION (US) 1988-06-08 EP claimed
US-4431497-A CARBO ALCOHOLS, ETHERS AND ESTERS AS STABILIZERS; STERILIZATION OF FOOD AND MEDICAL EQUIPMENT PACKAGES; DISCOLORATION INHIBITION MILLIKEN RESEARCH CORPORATION (US) 1984-02-14 US claimed
JP-1038455-A None JP disclosed
EP-4583876-A1 COMBINATION OF A T CELL THERAPY AND CONTINUOUS OR INTERMITTENT DGK INHIBITOR DOSING Juno Therapeutics, Inc. (US) 2025-07-16 EP disclosed
CN-120152717-A Combination of T cell therapy and continuous or intermittent DGK inhibitor administration 朱诺治疗学股份有限公司 2025-06-13 CN disclosed
WO-2025059098-A2 PHOTOCATALYTIC CARBOXYLATION OF SUBSTRATES WITH CARBON OXIDE NEW IRIDIUM INC. (US) 2025-03-20 WO disclosed
CN-112654621-B Substituted naphthyridinone compounds useful as T cell activators 百时美施贵宝公司 2024-05-14 CN disclosed
US-20240108654-A1 COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR JUNO THERAPEUTICS, INC. (US) 2024-04-04 US disclosed
WO-2024054944-A1 COMBINATION OF A T CELL THERAPY AND CONTINUOUS OR INTERMITTENT DGK INHIBITOR DOSING JUNO THERAPEUTICS, INC. (US) 2024-03-14 WO disclosed
CN-117693508-A Combination of T cell therapy and DGK inhibitors 朱诺治疗学股份有限公司 2024-03-12 CN disclosed
EP-4301755-A1 COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR Juno Therapeutics, Inc. (US) 2024-01-10 EP disclosed
EP-0252162-A1 PROCESS FOR PREPARING 2-UNSUBSTITUTED IMIDAZOLES MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1988-01-13 EP disclosed
EP-0231850-A2 Process for the formation of high contrast negative images and silver halide photographic element MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1987-08-12 EP disclosed
US-4603145-A Antiatherosclerotic diphenyl alkanamides AMERICAN CYANAMID COMPANY (US) 1986-07-29 US disclosed
US-4536346-A TREATMENT OF ATHEROSCLEROSIS AMERICAN CYANAMID COMPANY (US) 1985-08-20 US disclosed
EP-0124791-A1 Aralkanamidophenyl compounds AMERICAN CYANAMID COMPANY (US) 1984-11-14 EP disclosed
US-4431497-A CARBO ALCOHOLS, ETHERS AND ESTERS AS STABILIZERS; STERILIZATION OF FOOD AND MEDICAL EQUIPMENT PACKAGES; DISCOLORATION INHIBITION MILLIKEN RESEARCH CORPORATION (US) 1984-02-14 US disclosed
US-4138488-A Diphenylmethyl picolinic acid derivatives and their use as anti-acne agents SCHERING CORPORATION (US) 1979-02-06 US disclosed
US-3957434-A POLYAMIDES, POLYESTERS CIBA-GEIGY CORPORATION (US) 1976-05-18 US disclosed
JP-S06438455-A 0001-01-01 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240108654-A1 COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR DGKG, DGKA, DGKI ACHE 3607/4885TDP1 1911/4885CHRNA7 3018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.